Indian Journal of Endocrine Surgery and Research

Register      Login

VOLUME 16 , ISSUE 2 ( July-December, 2021 ) > List of Articles


Gastrointestinal Neuroendocrine Neoplasms

Supriya Sharma, Vinay K Kapoor

Keywords : Cancer, Gastrointestinal, Neuroendocrine

Citation Information : Sharma S, Kapoor VK. Gastrointestinal Neuroendocrine Neoplasms. 2021; 16 (2):51-58.

DOI: 10.5005/jp-journals-10088-11177

License: CC BY-NC 4.0

Published Online: 04-02-2022

Copyright Statement:  Copyright © 2021; The Author(s).


  1. Pictet RL, Rall LB, Phelps P, et al. The neural crest and the origin of the insulin-producing and other gastrointestinal hormone-producing cells. Science 1976;191(4223):191–192. DOI: 10.1126/science.1108195.
  2. Hiripi E, Lorenzo Bermejo J, Sundquist J, et al. Familial gastrointestinal carcinoid tumours and associated cancers. Ann Oncol 2009;20(5): 950–954. DOI: 10.1093/annonc/mdn706.
  3. Leoncini E, Carioli G, La Vecchia C, et al. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol 2016;27(1):68–81. DOI: 10.1093/annonc/mdv505.
  4. Jensen RT, Berna MJ, Bingham DB, et al. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008;113 (7 Suppl):1807–1843. DOI: 10.1002/cncr.23648.
  5. Kloppel G, Couvelard A, Perren A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009;90(2):162–166. DOI: 10.1159/000182196.
  6. Vanoli A, La Rosa S, Miceli E, et al. Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms: analysis of 200 cases with extended follow-up. Neuroendocrinology 2018;107(2): 114–126. DOI: 10.1159/000489902.
  7. Pape UF, Jann H, Müller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008;113(2):256–265. DOI: 10.1002/cncr.23549.
  8. Garbrecht N, Anlauf M, Schmitt A, et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 2008;15(1):229–241. DOI: 10.1677/ERC-07-0157.
  9. Donow C, Pipeleers-Marichal M, Schröder S, et al. Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type I, and malignancy. Cancer 1991;68(6): 1329–1334. DOI: 10.1002/1097-0142(19910915)68:6<1329::aid-cncr2820680624>;2-7.
  10. Strosberg J. Neuroendocrine tumours of the small intestine. Best Pract Res Clin Gastroenterol 2012;26(6):755–773. DOI: 10.1016/j.bpg.2012.12.002.
  11. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013;24(1):152–160. DOI: 10.1093/annonc/mds276.
  12. Niederle MB, Hackl M, Kaserer K, et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010;17(4):909–918. DOI: 10.1677/ERC-10-0152.
  13. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012;95(2):74–87. DOI: 10.1159/000335595.
  14. Kulke MH, Shah MH, Benson AB, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw 2015;13(1):78–108. DOI: 10.6004/jnccn.2015.0011.
  15. Kwon YH, Jeon SW, Kim GH, et al. Long-term follow up of endoscopic resection for type 3 gastric NET. World J Gastroenterol 2013;19(46):8703–8708. DOI: 10.3748/wjg.v19.i46.8703.
  16. Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 2005;19(5):675–697. DOI: 10.1016/j.bpg.2005.05.009.
  17. Randle RW, Ahmed S, Newman NA, et al. Clinical outcomes for neuroendocrine tumors of the duodenum and ampulla of Vater: a population-based study. J Gastrointest Surg 2014;18(2):354–362. DOI: 10.1007/s11605-013-2365-4.
  18. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97(4):934–959. DOI: 10.1002/cncr.11105.
  19. Yantiss RK, Odze RD, Farraye FA, et al. Solitary versus multiple carcinoid tumors of the ileum: a clinical and pathologic review of 68 cases. Am J Surg Pathol 2003;27(6):811–817. DOI: 10.1097/00000478-200306000-00013.
  20. Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 2011;8(1):54–64. DOI: 10.1038/nrendo.2011.120.
  21. Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 2010;39(6):753–766. DOI: 10.1097/MPA.0b013e3181ebb2a5.
  22. Ohrvall U, Eriksson B, Juhlin C, et al. Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg 2000;24(11):1402–1408. DOI: 10.1007/s002680010232.
  23. Norlen O, Hessman O, Stålberg P, et al. Prophylactic cholecystectomy in midgut carcinoid patients. World J Surg 2010;34(6):1361–1367. DOI: 10.1007/s00268-010-0428-1.
  24. Murray SE, Lloyd RV, Sippel RS, et al. Clinicopathologic characteristics of colonic carcinoid tumors. J Surg Res 2013;184(1):183–188. DOI: 10.1016/j.jss.2013.05.107.
  25. Ramage JK, Goretzki PE, Manfredi R, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology 2008;87(1):31–39. DOI: 10.1159/000111036.
  26. Konishi T, Watanabe T, Kishimoto J, et al. Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years. Gut 2007;56(6):863–868. DOI: 10.1136/gut.2006.109157.
  27. Washington MK, Tang LH, Berlin J, et al. Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the appendix. Arch Pathol Lab Med 2010;134(2):171–175. DOI: 10.5858/134.2.171.
  28. Sundin A, Arnold R, Baudin E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology 2017; 105(3):212–244. DOI: 10.1159/000471879.
  29. Oberg K, Couvelard A, Delle Fave G, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers. Neuroendocrinology 2017;105(3):201–211. DOI: 10.1159/000472254.
  30. Kaltsas G, Caplin M, Davies P, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology 2017;105(3):245–254. DOI: 10.1159/000461583.
  31. Plockinger U, Gustafsson B, Ivan D, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: echocardiography. Neuroendocrinology 2009;90(2):190–193. DOI: 10.1159/000225947.
  32. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26(18): 3063–3072. DOI: 10.1200/JCO.2007.15.4377.
  33. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27(28):4656–4663. DOI: 10.1200/JCO.2009.22.8510.
  34. Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0), Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res 2017;23(16):4617–4624. DOI: 10.1158/1078-0432.CCR-16-2743.
  35. Kratochwil C, Stefanova M, Mavriopoulou E, et al. SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol 2015;17(3):313–318. DOI: 10.1007/s11307-014-0795-3.
  36. Kennedy AS. Hepatic-directed therapies in patients with neuroendocrine tumors. Hematol Oncol Clin North Am 2016;30(1): 193–207. DOI: 10.1016/j.hoc.2015.09.010.
  37. Maxwell JE, Sherman SK, O'Dorisio TM, et al. Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy? Surgery 2016;159(1):320–333. DOI: 10.1016/j.surg.2015.05.040.
  38. Saxena A, Chua TC, Sarkar A, et al. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery 2011;149(2):209–220. DOI: 10.1016/j.surg.2010.06.008.
  39. Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review. Surgery 2017;162(3):525–536. DOI: 10.1016/j.surg.2017.05.006.
  40. Givi B, Pommier SJ, Thompson AK, et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery 2006;140(6):891–897; discussion 897–898. DOI: 10.1016/j.surg.2006.07.033.
  41. Berardi R, Rinaldi S, Torniai M, et al. Gastrointestinal neuroendocrine tumors: searching the optimal treatment strategy–a literature review. Crit Rev Oncol Hematol 2016;98:264–274. DOI: 10.1016/j.critrevonc.2015.11.003.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.